Insider trades
Neil Kumar, Director of BridgeBio Oncology Therapeutics BBOT, has filed 0 purchases and 163 sales on the open market. Over the past 12 months that comes to a net sale of $57.1M. The latest trade was on 06/16.
Neil Kumar
Director
- First filing
- 23/01/06
- Trades
- 262 trades
- Buys / sales
- 0 / 163
- 12-month net buying
- −$57.1M
- Last trade
- 06/16
Trading activity
Transactions
| Trade type | |||||||
|---|---|---|---|---|---|---|---|
BBIO | Open-market sale10b5-1 plan | 06/04–06/05 | 06/08 | 80,000 sh14 trades | $67.67avg. | $5,413,290.72 | −1.8% |
BBIO | Open-market sale10b5-1 plan | 05/21 | 05/26 | 26,103 sh5 trades | $69.44avg. | $1,812,475.26 | −9.7% |
BBIO | Open-market sale10b5-1 plan | 05/07–05/08 | 05/11 | 80,000 sh12 trades | $67.40avg. | $5,392,321.3 | −1.8% |
BBIO | Open-market sale10b5-1 plan | 04/09–04/10 | 04/13 | 80,000 sh8 trades | $74.61avg. | $5,968,524.04 | −1.8% |
BBIO | Open-market sale10b5-1 plan | 03/12–03/13 | 03/16 | 80,000 sh10 trades | $68.76avg. | $5,501,136.18 | −1.8% |
BBIO | Open-market sale10b5-1 plan | 02/19 | 02/23 | 28,053 sh3 trades | $71.39avg. | $2,002,624.53 | −10.7% |
BBIO | Open-market sale10b5-1 plan | 02/10–02/11 | 02/12 | 80,000 sh12 trades | $71.86avg. | $5,748,697.51 | −1.8% |
BBIO | Open-market sale10b5-1 plan | 01/08–01/09 | 01/12 | 80,000 sh14 trades | $75.54avg. | $6,043,174.18 | −1.7% |
BBIO | Open-market sale10b5-1 plan | 25/12/15 | 25/12/16 | 30,011 sh2 trades | $74.64avg. | $2,239,908.6 | −11.6% |
BBIO | Open-market sale10b5-1 plan | 25/12/04–25/12/05 | 25/12/08 | 80,000 sh10 trades | $73.86avg. | $5,908,431.49 | −1.7% |
BBIO | Open-market sale10b5-1 plan | 25/11/20 | 25/11/24 | 26,156 sh3 trades | $65.84avg. | $1,722,146.83 | −10.3% |
BBIO | Open-market sale10b5-1 plan | 25/11/06–25/11/07 | 25/11/10 | 80,000 sh12 trades | $62.29avg. | $4,983,192.59 | −9.1% |
BBIO | Open-market sale10b5-1 plan | 25/10/08–25/10/09 | 25/10/10 | 80,000 sh6 trades | $54.79avg. | $4,383,412.3 | −8.7% |
BBIO | Open-market sale10b5-1 plan | 25/09/04–25/09/05 | 25/09/08 | 80,000 sh10 trades | $52.20avg. | $4,175,732.48 | −8.4% |
BBIO | Open-market sale10b5-1 plan | 25/08/20 | 25/08/22 | 26,156 sh2 trades | $48.82avg. | $1,276,862.68 | −10.5% |
BBIO | Open-market sale10b5-1 plan | 25/08/07–25/08/08 | 25/08/11 | 80,000 sh8 trades | $45.84avg. | $3,666,957.9 | −8.0% |
BBIO | Open-market sale10b5-1 plan | 25/07/01–25/07/02 | 25/07/03 | 80,000 sh6 trades | $42.63avg. | $3,410,654 | −7.7% |
BBIO | Open-market sale10b5-1 plan | 25/05/19–25/05/20 | 25/05/20 | 101,156 sh3 trades | $33.38avg. | $3,376,689.92 | No record |
BridgeBio PharmaBBIO | Open-market sale10b5-1 plan | 25/04/22 | 25/04/24 | 75,000 sh | $34.11 | $2,558,250 | −1.5% |
BridgeBio PharmaBBIO | Open-market sale10b5-1 plan | 25/03/25 | 25/03/27 | 75,000 sh | $36.87 | $2,765,250 | −1.5% |
